In the traditional central dogma, cellular behavior is often viewed through the lens of gene expression: more mRNA leads to more protein, which leads to more activity. However, research across dozens of recent studies reveals that cancer cells and regenerating tissues frequently bypass this transcriptional control. Instead, they regulate the "trash" — specifically, they use enzymes called deubiquitinases (DUBs) to rescue critical proteins from the cellular recycling bin.
By removing ubiquitin tags that mark proteins for destruction, DUBs act as molecular bodyguards, sustaining high levels of oncogenic transcription factors and kinases even when their underlying gene expression remains unchanged.
The Proteasomal Tug-of-War
To understand why this mechanism is so effective, we must look at the protein lifecycle as a constant tug-of-war. Most regulatory proteins are inherently unstable; they are tagged with polyubiquitin chains (often K48-linked) by E3 ubiquitin ligases, which signals the 26S proteasome to grind them up.
DUBs provide the counter-force. As Yuchong Peng and colleagues demonstrated in their study of USP7, these enzymes physically bind to target substrates and enzymatically "clip" the ubiquitin chains. In the case of the mitotic master regulator PLK1, USP7-mediated stabilization ensures the protein survives long enough to orchestrate chromosome alignment. Without this intervention, PLK1 levels drop, the cell cycle stalls, and the cell may undergo apoptosis.
DUBs as Switches for Cellular Identity
This stabilization mechanism is particularly potent when it targets transcription factors that define a cell's identity. In aggressive cancers, DUBs are often hijacked to maintain the "mesenchymal" state that allows cells to migrate and invade.
For instance, the transcription factor ZEB1 is a notorious driver of the epithelial–mesenchymal transition (EMT). Multiple researchers have found that ZEB1 levels are maintained not just by transcription, but by specific DUB "shields":
- Kai Zeng identified USP22 as a stabilizer of ZEB1 in liver cancer, driving both invasion and blood vessel growth.
- Ruting Wei found that ATXN3 performs a similar role in glioblastoma, preventing ZEB1 degradation to facilitate brain tumor spread.
Similarly, the Hippo pathway effector TAZ is protected by USP1 in osteosarcoma, as shown by Putao Yuan, and by UCHL1 in bone-remodeling cells, as detailed by Siyue Tao. In all these cases, the DUB acts as a post-translational rheostat, keeping the "on" switch for growth and invasion firmly in place.
Scaffolds and the Regulation of Stability
The interaction between a DUB and its target is rarely a simple two-body problem. The cell uses "scaffold" proteins and non-coding RNAs to recruit DUBs to their targets or to shield them from competing E3 ligases.
BIN CHEN and colleagues illustrated this in their work on RRM1. They found that RRM1 acts as a scaffold that modulates the binding affinity of opposing enzymes to p53. When this scaffold is disrupted, the balance shifts from DUB-mediated stabilization to ligase-mediated degradation, sensitizing cancer cells to treatment.
Furthermore, long non-coding RNAs (lncRNAs) can act as recruitment platforms. Guohua Jin showed that the lncRNA SND1-IT1 travels via exosomes to healthy cells, where it recruits DUBs to stabilize the SNAIL1 protein, effectively "infecting" healthy tissue with a metastatic phenotype.
Therapeutic Implications: Destabilization as Strategy
The clinical appeal of this research direction lies in the "druggability" of the DUB-substrate interface. While transcription factors themselves are notoriously difficult to target with small molecules, the enzymes that stabilize them are often viable targets.
By inhibiting a specific DUB, researchers can indirectly "delete" an oncogenic protein. Putao Yuan demonstrated that using the small molecule ML323 to inhibit USP1 successfully destabilized TAZ and suppressed tumor growth in animal models. This approach—moving from "blocking the function" of a protein to "removing the protein entirely" by withdrawing its DUB protection—represents a significant shift in precision oncology.
Whether it is USP43 suppressing ferroptosis in ovarian cancer or USP14 driving diabetic retinopathy, the core mechanism remains the same: the cell's ability to persist in a pathological state depends on its ability to keep its regulatory proteins out of the proteasome. Understanding these stabilization axes provides a roadmap for collapsing the signaling networks that sustain disease.